Lilly pays $35M up front to partner with Avidity on oligo conjugates

Lilly pays $35M up front to partner with Avidity on oligo conjugates

Submitted by admin on April 22, 2019 - 10:24am
Source: 
BioCentury
News Tags: 
Eli Lilly
Avidity
oligo conjugates
Headline: 
Lilly pays $35M up front to partner with Avidity on oligo conjugates
snippet: 

Lilly partnered with Avidity to develop antibody-oligonucleotide conjugates to treat immune diseases, with the biotech receiving $20 million up front and Eli Lilly and Co. (NYSE:LLY) also investing $15 million.